In the presence of CD44 N-glycan α-(2,6)-linked sialic acid modifications, Siglec-15 interacts with CD44 and mediates liver cancer progression and metastasis by preventing CD44 lysosome-mediated degradation (125). Here, CD44 is linked to liver cancer.